Renier J. Brentjens
雷尼尔·布伦特延斯
MD, PhD
Director, Cellular Therapeutics Center; Attending Physician, Leukemia Service细胞治疗中心主任；白血病科主治医师
👥Biography 个人简介
Renier Brentjens co-developed the original CD19 CAR-T cell construct at MSK and led some of the earliest clinical trials demonstrating remarkable complete remissions in relapsed/refractory ALL. His pioneering work established CD19 CAR-T as a potential cure for B cell malignancies.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Original CD19 CAR-T Design
Co-developed early CD19-targeted CAR constructs with CD28/CD3ζ signaling domains at MSK and conducted first human trials showing complete responses in relapsed ALL patients.
CAR-T for Adult ALL
Demonstrated 88% complete remission rate with CD19 CAR-T in adult relapsed/refractory B-ALL, including patients who subsequently received allogeneic stem cell transplantation.
Representative Works 代表性著作
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
Blood (2011)
First clinical report from MSK of CD19 CAR-T safety and persistence in CLL and ALL patients, establishing clinical feasibility.
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia
Science Translational Medicine (2013)
Reported high complete remission rates in adult ALL using CD19 CAR-T, demonstrating remarkable efficacy in a historically difficult-to-treat population.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 雷尼尔·布伦特延斯 的研究动态
Follow Renier J. Brentjens's research updates
留下邮箱，当我们发布与 Renier J. Brentjens（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment